Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment. [electronic resource]
Producer: 20140407Description: 1146-53 p. digitalISSN:- 1941-837X
- Adolescent
- Adult
- Antibodies, Monoclonal, Humanized -- economics
- Cohort Studies
- Confidence Intervals
- Contracts -- economics
- Feasibility Studies
- Female
- Hospitalization -- economics
- Humans
- Immunosuppressive Agents -- economics
- Insurance Claim Review -- economics
- Interferon-beta -- economics
- Male
- Middle Aged
- Multiple Sclerosis, Relapsing-Remitting -- diagnosis
- Natalizumab
- Observation -- methods
- Odds Ratio
- Outcome Assessment, Health Care -- economics
- Poisson Distribution
- Predictive Value of Tests
- Prognosis
- Recurrence
- Retrospective Studies
- Risk Management
- Severity of Illness Index
- Time Factors
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.